A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
Status:
Recruiting
Trial end date:
2022-09-16
Target enrollment:
Participant gender:
Summary
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center
clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release
Tablets in patients with Parkinson's disease. The objective of the study is to access the
safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with
Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai WD Pharmaceutical Co., Ltd.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa